Safety and effectiveness of the radium-223–taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)

Safety and effectiveness of the radium-223–taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)

Radium-223 and taxane chemotherapy each improve survival of patients with metastatic castration-resistant prostate cancer (mCRPC). Whether the radium-223–taxane sequence could extend survival without cumulative toxicity was explored.
The global, prospective, observational REASSURE study (NCT02141438) assessed real-world safety and effectiveness of radium-223 in patients with mCRPC. Using data from the prespecified second interim analysis (data cutoff, March 20, 2019), hematologic events and overall survival (OS) were evaluated in patients who were chemotherapy-naive at radium-223 initiation and subsequently received taxane chemotherapy starting ≤90 days (“immediate”) or >90 days (“delayed”) after the last radium-223 dose.
Following radium-223 therapy, 182 patients received docetaxel (172 [95%]) and/or cabazitaxel (44 [24%]); 34 patients (19%) received both. Seventy-three patients (40%) received immediate chemotherapy and 109 patients (60%) received delayed chemotherapy. Median time from last radium-223 dose to first taxane cycle was 3.6 months (range, 0.3–28.4). Median duration of first taxane was 3.7 months (range, 0–22.0). Fourteen patients (10 in the immediate and four in the delayed subgroup) had grade 3/4 hematologic events during taxane chemotherapy, including neutropenia in two patients in the delayed subgroup and thrombocytopenia in one patient in each subgroup. Median OS was 24.3 months from radium-223 initiation and 11.8 months from start of taxane therapy.
In real-world clinical practice settings, a heterogeneous population of patients who received sequential radium-223–taxane therapy had a low incidence of hematologic events, with a median survival of 1 year from taxane initiation. Thus, taxane chemotherapy is a feasible option for those who progress after radium-223. This paper shows the potential value of this approach to help provide guidance in making decisions. Prospective randomised studies, adequately designed and run, will continue to provide the ‘gold standard’, but the reality is that such studies will provide answers in the future, when those who practice need the guidance now.

READ THE ARTICLE – https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.35221

Share this post